ReviewSmart medicine2024
Drug-phospholipid conjugate nano-assembly for drug delivery.
Review in Smart medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Article
- Layer-Specific Dermal and Subcutaneous Delivery via Modular LNP-Hydrogel-Integrated Threaded Microneedles.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Biomaterial-Integrated Electroporation for Therapeutic Delivery: From Gene Editing to Tumor Ablation and Immune Modulation.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Nuclear-Mitochondria Crosstalk in Senescent Adipose-Derived Stem Cells.Smart medicine · 2026Review
- Boosting ribosomal translationBioactive materials · 2026Article
- Covalent conjugation of TLR9 agonists to phospholipids enhances mRNA-LNP delivery efficiency and dendritic cell cross-priming.Journal of nanobiotechnology · 2026Article
- Charge/stiffness-tunable nano-microsphere overcomes intestinal mucosal barrier for rheumatoid arthritis treatment.Materials today. Bio · 2026Article
- In-situ RhoA editing via heparinylated LNP-microsphere system for rheumatoid arthritis treatment.Journal of nanobiotechnology · 2026Article
- Biomedical Technologies for Androgenic Alopecia Treatment: Advance, Mechanism and Future Direction.Research (Washington, D.C.) · 2026Review
- Engineered Inner Ear Drug Delivery Systems for Hearing Loss Treatment.Research (Washington, D.C.) · 2026Review
- Ultrasound-Responsive Microcapsules Delivering Oxygen and Traditional Chinese Medicine for Wound Healing.Smart medicine · 2025Article
- Drug-phospholipid conjugate nano-assembly for drug delivery.Smart medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phospholipid-based liposomes are among the most successful nanodrug delivery systems in clinical use. However, these conventional liposomes present significant challenges including low drug-loading capacity and issues with drug leakage. Drug-phospholipid conjugates (DPCs) and their assemblies offer a promising strategy for addressing these limitations. In this review, we summarize recent advances in the design, synthesis, and application of DPCs for drug delivery. We begin by discussing the chemical backbone structures and various design strategies such as phosphate head embedding and mono-/bis-embedding in the sn-1/sn-2 positions. Furthermore, we highlight stimulus-responsive designs of DPCs and their applications in treating diseases such as cancer, inflammation, and malaria. Lastly, we explore future directions for DPCs development and their potential applications in drug delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.